In vitro,in vivoandex vivocharacterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1

CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function

(2014) Shang-jun Tang et al.   BIOCHEMICAL PHARMACOLOGY

Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10-Mediated Paclitaxel Resistance: A Preclinical Study

(2014) R. J. Kathawala et al.   MOLECULAR CANCER THERAPEUTICS

The Concise Guide to PHARMACOLOGY 2013/14: Transporters

(2013) Stephen P.H. Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Concise Guide to PHARMACOLOGY 2013/14: Enzymes

(2013) Stephen P.H. Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells

(2013) Atish Patel et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Ibrutinib and novel BTK inhibitors in clinical development

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Targeting the B-cell signalling pathway in CLL and MCL

(2013) Sharan Prakash Sharma   LANCET ONCOLOGY

Cancer's true breakthroughs

(2013) Elie Dolgin   NATURE MEDICINE

The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands

(2013) Adam J. Pawson et al.   NUCLEIC ACIDS RESEARCH

GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance

(2012) Kamlesh Sodani et al.   BIOCHEMICAL PHARMACOLOGY

Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models

(2012) Amit K. Tiwari et al.   CANCER LETTERS

Blockade of Her2/neuBinding to Hsp90 by Emodin Azide Methyl Anthraquinone Derivative Induces Proteasomal Degradation of Her2/neu

(2011) Yan-yan Yan et al.   MOLECULAR PHARMACEUTICS

Multidrug resistance associated proteins in multidrug resistance

(2011) Kamlesh Sodani et al.   Chinese Journal of Cancer

Bovine microsatellite dinucleotide repeat polymorphisms at the TEXAN16, TEXAN17, TEXAN18, TEXAN19 and TEXAN20 loci

(2010) B. M. Burns et al.   ANIMAL GENETICS

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters

(2010) Y.-j. Mi et al.   CANCER RESEARCH

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MRP1 polymorphisms (T2684C, C2007T, C2012T, and C2665T) are not associated with multidrug resistance in leukemic patients

(2009) F. Mahjoubi et al.   GENETICS AND MOLECULAR RESEARCH

Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function

(2009) Li-sheng Zheng et al.   PLoS One

Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae

(2008) Min Huang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

(2008) C.-l. Dai et al.   CANCER RESEARCH